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Abstract: Pregnancies carried by women with chronic hypertension are at increased risk of super-
imposed preeclampsia, but the placental pathways involved in disease progression remain poorly
understood. In this study, we used the stroke-prone spontaneously hypertensive rat (SHRSP) model
to investigate the placental mechanisms promoting superimposed preeclampsia, with focus on cellu-
lar stress and its influence on galectin–glycan circuits. Our analysis revealed that SHRSP placentas
are characterized by a sustained activation of the cellular stress response, displaying significantly
increased levels of markers of lipid peroxidation (i.e., thiobarbituric acid reactive substances (TBARS))
and protein nitration and defective antioxidant enzyme expression as early as gestation day 14 (which
marks disease onset). Further, lectin profiling showed that such redox imbalance was associated with
marked alterations of the placental glycocode, including a prominent decrease of core 1 O-glycan
expression in trophoblasts and increased decidual levels of sialylation in SHRSP placentas. We also
observed significant changes in the expression of galectins 1, 3 and 9 with pregnancy progression,
highlighting the important role of the galectin signature as dynamic interpreters of placental microen-
vironmental challenges. Collectively, our findings uncover a new role for the glycoredox balance in
the pathogenesis of superimposed preeclampsia representing a promising target for interventions in
hypertensive disorders of pregnancy.
Keywords: chronic hypertension; placenta; preeclampsia; oxidative stress; glycosylation
1. Introduction
With a global prevalence of 1 to 5%, chronic hypertension during pregnancy con-
tributes to a significant healthcare economic burden associated with poor maternal and
perinatal outcomes. Adverse outcomes are mostly due to progression to superimposed
preeclampsia (SPE) which occurs in 25–40% of pregnancies affected by chronic hyperten-
sion [1]. Accurate diagnosis of SPE is still challenging, but the condition is presumed upon
worsening of the hypertensive state associated with signs of end-organ damage includ-
ing proteinuria and renal insufficiency, liver involvement, neurological disturbances or
uteroplacental dysfunction and fetal growth restriction (FGR), presenting usually as early
onset disease (i.e., before the 34th week) [1,2]. As obesity rates and maternal childbearing
age continue to rise, chronic hypertension with SPE is expected to remain a major cause of
morbidity and mortality among women and their offspring [3,4].
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The core event in preeclampsia pathogenesis is placental malperfusion [5], which
originates from early defects in the physiological conversion of maternal spiral arteries
mediated by invasive trophoblast cells. At the second stage, ischemia–reperfusion damage
of the placenta with oxidative/endoplasmic reticulum stress enhances the release of soluble
mediators that trigger the systemic inflammatory cascade and endothelial dysfunction
ultimately responsible for the maternal syndrome [6,7]. While the specific mechanisms
promoting SPE are still largely unknown, evidence from clinical studies [8–10] and, more
recently, animal models of chronic hypertension [11–13] point out to the involvement of
placental cellular and molecular pathways largely overlapping those described for the de
novo syndrome.
Dysregulated redox responses are involved in the initiation and progression of many
inflammatory diseases including preeclampsia [14]. Recent findings indicate that changes
in the production of reactive oxygen species (ROS) due to the activation of cellular stress
response (CSR) pathways contribute to the regulation of glycan functions [15]. Glycans are
crucial determinants of cell function and the glycocode expressed in a particular compart-
ment (e.g., placenta) is a dynamic reflection of its developmental and pathophysiological
status [16]. In the placenta, glycans modify proteins required for trophoblast function and
altered glycosylation has been associated with pathological conditions including different
types of hypertensive disorders of pregnancy and fetal growth restriction [17–19]. As
paramount “interpreters” of the glycocode, members of the galectin family of β-galactoside
binding proteins have attracted great attention due to their unique ability to modulate
developmental processes supporting pregnancy maintenance and their potential use as
disease biomarkers (reviewed in [20]). Of particular interest in the context of preeclamp-
sia is the role played by galectin–glycan circuits in the modulation of pro-survival and
pro-apoptotic pathways [21,22], a function essential for cellular homeostasis under mi-
croenvironmental insults ranging from metabolic imbalance and local hypoxia to oxidative
stress. Indeed, several of the galectins most abundantly expressed at the maternal fetal
interface (i.e., Gal-1, Gal-3, Gal-9 and Gal-13) are considered markers of the CSR, acting as
“alarmin-like” molecules to signal tissue damage and promote an effector response from
immune cells [23–26]. In this context, dynamic changes in the galectin–glycan network
associated with an overall CSR and redox imbalance upon placental malperfusion could
play an important role in the pathogenesis of preeclampsia.
In this study, we used the stroke-prone spontaneously hypertensive rat (SHRSP)
model for essential hypertension that displays an SPE phenotype during pregnancy [11].
SHRSP pregnancies are also characterized by early defects in trophoblast invasion leading
in turn to placental dysfunction, asymmetric FGR and a maternal syndrome with increased
hypertension and proteinuria towards term [11]. We investigated the involvement of
placental redox imbalance and the CSR in SPE pathogenesis and characterized the dynamic
changes in the expression profile of glycans and stress-sensitive galectins in the placenta
associated with disease progression to shed light on the mechanisms promoting SPE.
2. Materials and Methods
2.1. Animals and Experimental Design
This follow-up study was conducted using samples collected for our previous work on
the characterization of SHRSP pregnancies as a spontaneous model of chronic hypertension
with SPE [11]. Timed pregnancies were established by cohabitation of nulliparous SHRSP
and Wistar Kyoto (WKY, normotensive controls) females (8–12-week-old, 200–250 g body
weight) with congenic males, denoting the morning of detection of a vaginal plug as
gestation day (GD) 1. Maternal systolic blood pressure (SBP) profiles throughout pregnancy
were established as described previously [11]. A total of 37 WKY and 44 SHRSP breeding
pairs were used, so that n = 5–7 pregnant animals per GD were included in the study.
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2.2. Tissue Collection
Rats were euthanized on GD14 or GD18 while under thiopental sodium anesthesia
for collection of fetoplacental samples. The uterus was dissected exposing the fetoplacental
units, and whole implantation sites were prepared by carefully separating each unit (i.e.,
the placenta with its associated mesometrial triangle and decidual tissue). Fetoplacental
specimens were fixed in phosphate-buffered 10% formaldehyde (pH 7.2) and embedded in
paraffin according to the standard methods for histological sectioning [27].
2.3. Determination of Thiobarbituric Acid Reactive Substances (TBARS)
The assay was based on a previously described method [28]. Briefly, the samples were
mixed with 3% (w/v) sodium dodecyl sulfate (SDS), 0.1 N HCl, 10% (w/v) phosphotungstic
acid and 0.7% (w/v) 2-thiobarbituric acid and heated for 45 min in boiling water; TBARS were
extracted with 2 mL of n-butanol and detected fluorometrically (λex: 515 nm; λem: 555 nm).
To prepare the standard of malondialdehyde, 1,1,3,3-tetramethoxypropane was used. The
results were expressed as TBARS nmol (malondialdehyde equivalents)/mg protein.
2.4. Immunohistochemistry for Oxidative Stress Markers, Antioxidant Enzymes and Galectins
Paraffin-embedded implantation sites were sectioned (4-µm-thick) parallel to the
mesometrial–fetal axis and inmunolabeled following a modified avidin–biotin–peroxidase
complex technique using a Vectastain ABC kit (Universal Elite; Vector Laboratories,
Burlingame, CA, USA). Following deparaffinization and rehydration, the sections were
washed in PBS for 5 min. Quenching of endogenous peroxidase (PO) activity was achieved
by incubating the sections for 30 min in 1% H2O2 in methanol. The sections were then
washed in PBS (pH 7.2) for 20 min, followed by incubation with blocking serum for 20 min.
The sections were then incubated with primary antibodies against nitrotyrosine (#MAB5404;
Millipore, Burlington, MA, USA), Hsp27 (sc-1048), Hsp70 (sc-1060, both from Santa Cruz
Biotechnology, Dallas, TX, USA), peroxiredoxin (ab15571) or thioredoxin (ab86255, both
from Abcam, Cambridge, UK) overnight at 4 ◦C, rinsed in PBS and incubated with a
biotinylated universal antibody for 30 min. The specimens were washed in PBS, incubated
for 40 min with a Vectastain Elite ABC reagent (Vector Laboratories) and exposed for 5 min
to 0.1% diaminobenzidine (Polysciences, Warrington, PA, USA) and 0.2% H2O2 in 50 mM
Tris buffer, pH 8. After washing, the nuclei were counterstained with 0.1% Mayer’s hema-
toxylin, followed by a standard dehydration procedure and mounting in a DPX histology
medium (Millipore-Sigma, St. Louis, MO, USA).
Immunostaining for galectin expression was achieved following our standard pro-
tocol [29]. Briefly, the sections were deparaffinized and rehydrated, washed in TBS and
blocked for quenching endogenous peroxidase activity. After blocking with 2% normal
serum for 20 min, primary antibodies against Gal-1 (sc-28248), Gal-3 (sc-20157) or Gal-9
(sc-19292, all from Santa Cruz Biotechnology) were incubated overnight at 4 ◦C. The slides
were then incubated for 1 h at room temperature with a goat anti-rabbit PO-conjugated
secondary antibody (1:200, cat. #111-035-003, Jackson ImmunoResearch, West Grove, PA,
USA) for Gal-1 and Gal-3 determination or a donkey anti-goat PO-conjugated secondary
antibody (1:200, cat. #705-035-147, Jackson ImmunoResearch) for Gal-9. The signal was de-
tected using a liquid diaminobenzidine (DAB+) Substrate Chromogen System (cat. #K3467,
DAKO, Glostruck, Denmark) at room temperature. The nuclei were counterstained with
0.1% Mayer’s hematoxylin followed by a standard dehydration procedure and mounting
in a Vitro-Clud medium (R. Langenbrinck GmbH, Emmendingen, Germany).
2.5. Western Blots
Placental samples were homogenized in a lysis buffer (150 mM NaCl, 50 mM Trizma–
HCl, 1% (v/v) NP-40, pH 8.0) in the presence of protease and phosphatase inhibitors and
centrifuged at 600× g for 20 min. The samples containing the same protein concentration
were added with a 2X solution of the sample buffer (62.5 mM Tris–HCl, pH 6.8, containing
2% (w/v) SDS, 25% (w/v) glycerol, 5% (v/v) β-mercaptoethanol and 0.01% (w/v) bromophe-
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nol blue) and heated at 95 ◦C for 2 min. Sample aliquots containing 30 µg of protein were
separated by reducing 10% (w/v) polyacrylamide gel electrophoresis and electroblotted to
polyvinylidene difluoride membranes. Colored molecular weight standards (GE Health-
care, Piscataway, NJ, USA) were run simultaneously. The membranes were blotted for 2 h
in 5% (w/v) nonfat milk incubated overnight in the presence of the corresponding primary
antibody: phospho-p47phox (Ser370; #PA5-38798, Invitrogen, Waltham, MA, USA), SOD1
(AB1237, Chemicon International, Temecula, CA, USA), p47phox, SOD2 and β-actin (#7660,
#133134, #47778, Santa Cruz Biotechnology, CA, USA), all used in a 1:1000 dilution in PBS.
After a subsequent incubation for 90 min at room temperature (RT) in the presence of the
corresponding HRP-conjugated secondary antibody (mouse anti-rabbit IgG-HRP or goat
anti-mouse IgG-HRP (#2357, #2005; Santa Cruz Biotechnology, 1:5000), the complexes were
visualized by chemiluminescence. The films were scanned and a densitometric analysis
was performed using ImageJ (National Institutes of Health, Bethesda, MD, USA). Band
densities were normalized to the β-actin content.
2.6. Glycan Profiling by Lectin-Binding Analysis
Glycan profiling was performed as described previously [30]. O-glycan structures
were determined using the Helix pomatia agglutinin (HPA; Tn antigen) and the Arachis
hypogaea lectin (PNA; core 1). Binding of the Lycopersicon esculentum lectin (LEA) was used
for the detection of polyLacNAc extensions (carried by core 2 O- and complex N-glycans).
In addition, binding of the Phaseolus vulgaris lectin (PHA-L) was used for determination
of β1,6-GlcNAc-branched complex N-glycans and sialyation was determined using the
Maackia amurensis lectin (MAA) and the Sambucus nigra agglutinin (SNA-I), which recognize
α2,3- and α2,6-linked sialic acid, respectively. Briefly, the slides were deparaffinized,
rehydrated, washed in PBS and blocked with PBS, 5% BSA, 1% fish gelatin, for 20 min in
a humid chamber at RT. Afterwards, the slides were blocked with a Carbo-Free Blocking
Solution (SP-5040, Vector Laboratories) for 30 min at RT. Subsequently, the slides were
incubated with biotinylated lectins HPA (20 ng/mL; BA-3601-1), PHA-L (20 ng/mL; BA-
1801-2) or SNA-I (10 ng/mL; BA-6802-1, all from EY Laboratories) diluted in a Carbo-Free
Blocking Solution overnight at 4 ◦C. Lectin-stained sections were then incubated with
2µg/mL streptavidin–tetramethylrhodamine (S-870; Invitrogen) for 1 h at RT. Subsequently,
the slides were incubated with fluorescein isothiocyanate (FITC)-labeled lectins PNA
(20 ng/mL; F-2301-1), LEA (20 ng/mL; F-7001-1) or MAA (20 ng/mL; F-7801-2, all from
EY Laboratories) diluted in a Carbo-Free Blocking Solution for 2 h at RT. The nuclei were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) for 5 min at RT and the slides
were mounted in Prolong Gold (P36930, Invitrogen). Stainings of whole implantation
sites were digitally scanned with a high-resolution bright field and fluorescence slide
scanner (Pannoramic MIDI BF/FL, 3DHISTECH Ltd., Budapest, Hungary), and staining
was evaluated on virtual slides using Pannoramic Viewer 1.15.4 (3DHISTECH Ltd.) by
two examiners blinded to the experimental group.
2.7. Morphometrical Analyses
Photodocumentation was performed using either the Nikon E400 (Nikon Instrument
Group, Melville, NY, USA) or the Keyence BZ 9000 (Keyence Corporation, Itasca, IL, USA)
microscope systems. All the measurements were made on one set of five serial parallel
sections taken through the center of the placental site (as indicated by the presence of
a maternal spiral artery in the decidual layer) and perpendicular to its flat (fetal) side.
For all the markers, staining localization was assessed by two independent observers
taking into account their distribution in the maternal (decidua, mesometrial triangle) and
fetal (junctional zone, labyrinth) compartments of the placenta. Quantitative analyses
were performed on a set of at least ten random images taken at ×200 magnification
from each compartment (mesometrial triangle for maternal and labyrinth layer for fetal
sources, respectively) and run using the color deconvolution plugin of the ImageJ software
(National Institutes of Health, https://imagej.nih.gov/, accessed on 3 April 2021). All
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the results for histological staining were expressed as the percentage of area with positive
immunostaining within each placental compartment.
2.8. Statistics
Data are expressed as the means ± SEM. Between-group differences were assessed
by unpaired Student’s t-tests. Temporal changes in marker expression through gestation
were analyzed using two-way ANOVA with factors strain (WKY vs. SHRSP) and GD and
their interaction, followed by Bonferroni post-hoc tests. All the calculations were run using
GraphPad Prism v 7.0 (GraphPad Software Inc., San Diego, CA, USA). A p-value of less
than 0.05 was considered statistically significant.
3. Results
3.1. Onset of SPE in SHRSP Pregnancies Is Marked by an Enhanced Activation of the
Placental CSR
Our analyses of SHRSP pregnancies focused on two specific gestational stages
(Figure 1).
Figure 1. Summary of the superimposed preeclampsia (PE)-like features observed in SHRSP preg-
nancies. Gestation day (GD) 14 corresponds to the onset of disease, characterized by defective
placentation and impaired arterial remodeling defects without full development of maternal fea-
tures. As pregnancy progresses towards GD18, blood pressure rises steadily presenting the typical
features observed in superimposed preeclampsia: aggravated hypertensive condition, end-organ
damage (i.e., renal dysfunction with glomerular enlargement and proteinuria) and FGR (described in
detail in [11]).
GD14 denotes the onset of SPE characterized by placentation and spiral artery re-
modeling defects without full development of maternal features and GD18 represents the
established maternal syndrome with end-organ (i.e., renal) damage [11].
First, we evaluated the expression of markers for the CSR (Figure 2A) to investigate
the involvement of placental stress and redox imbalance in SPE pathogenesis.
In both pregnancy models, progression of pregnancy from GD14 to GD18 was asso-
ciated with a significant increment of placental levels of TBARS (Figure 2B), indicating
increased lipid peroxidation. However, levels of TBARS on GD14 were 2-fold higher in
SHRSP placentas compared to the controls (p < 0.05, Figure 2B) and remained increased as
gestation progressed to GD18. Further, immunohistochemical analyses showed that SHRSP
implantations displayed a significant increase of protein nitrotyrosine (pNT) residues on
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GD14 both in the maternal (mesometrial triangle, Figure 2C, upper panel) and placental
(junctional zone and labyrinth, Figure 2C, bottom panel) compartments, indicating in-
creased nitrosative stress. Notably, normal pregnancy progression was associated with a
significant upregulation of pNT levels (p < 0.001, Figure 2C, bottom panel) in the placental
labyrinth from GD14 to GD18. This upregulation was abrogated in SHRSP placentas,
in which pNT immunolabeling remained at similar levels as gestation progressed from
GD14 to GD18. The onset of SPE was also associated with augmented expression of the
CSR chaperones Hsp27 and Hsp70 (Figure 2D) in SHRSP pregnancies, with a differential
distribution in the maternal and placental compartments: while the mesometrial triangle
displayed significantly increased Hsp27 (Figure 2D, left upper panel) but no differences
in Hsp70 immunolabeling (Figure 2D, left bottom panel), both markers were significantly
upregulated in the placental junctional zone and labyrinth compared to WKY. While in both
models the expression of Hsp27 increased significantly from GD14 to GD18 (Figure 2D,
left upper panel), levels of Hsp70 expression in the mesometrial triangle did not vary with
pregnancy progression and were similar in both mating models (Figure 2D, left bottom
panel). In the placental compartment, in contrast, SHRSP displayed reduced levels of
Hsp70 expression compared to WKY implantations on GD18 (Figure 2D, right bottom
panel). Furthermore, Western blot analyses revealed that normal pregnancy progression
was associated with a significant upregulation of phosphorylated p47phox (Figure 2E) from
GD14 to GD18, indicating increased NADPH oxidase 2 (NOX2) activation. Of note, the
normal upregulation of phospho-p47phox from GD14 to GD18 was abrogated in SHRSP
placentas, which displayed similarly high levels of expression on both days analyzed.
Next, we evaluated changes in the expression of antioxidant defense systems asso-
ciated with progression of SPE in the SHRSP model. As shown in Figure 3A, placental
expression of the protective ROS-detoxifying systems SOD1 (left panel), SOD2 (middle
panel) and catalase (right panel) was upregulated from GD14 to GD18 in normally progress-
ing WKY pregnancies. SHRSP implantations exhibited a similar response except for the
expression of SOD2 (Figure 3A, middle panel), which showed no changes with pregnancy
progression and was significantly decreased on GD18 compared to normal pregnancies.
Additionally, SHRSP implantations presented significantly decreased immunolabeling for
peroxiredoxin 1 on GD14 (PRX, Figure 3B), which was evident both in the mesometrial
triangle and the junctional zone and labyrinth layer. Expression of thioredoxin (TRX,
Figure 3C) was also diminished at the onset of SPE in the SHRSP model, but only in the
maternal compartment. In the placental compartments, in contrast, SHRSP implantations
displayed an upregulation of TRX expression with progression of pregnancy from GD14 to
GD18 (Figure 3C, right panel).
3.2. Marked Changes in Placental Glycosylation Associated with the Onset of SPE in
SHRSP Pregnancies
Next, we performed lectin-based stains to profile the placental expression of glycans in
both models (Figure 4A). In normal pregnancies, we observed a significant downregulation
of the Tn antigen (HPA, Figure 4B upper panels) and polyLacNAc extensions (LEA, bottom
panels) in the decidua together with upregulated expression of the Thomsen-Friedenreich
(TF) epitope (PNA, middle panels) in the mesometrial triangle with pregnancy progression.
In the placenta, there were no changes in glycan expression from GD14 to GD18 except for
a significant increase of TF expression in the labyrinth layer (Figure 4B, middle panels). In
SHRSP, the onset of SPE on GD14 was marked by significantly reduced levels of TF expres-
sion in all maternal and placental compartments. Furthermore, as gestation progressed
to GD18, there was a significant upregulation of TF levels in the placental giant cells and
spongiotrophoblasts of the junctional zone (Figure 4B, middle panels). On GD18, SHRSP
placentas displayed significantly decreased Tn antigen levels in the labyrinth (Figure 4B,
upper panels), reduced TF expression in the mesometrial triangle and labyrinth (middle
panels) and decreased levels of polyLacNAc-extended glycans in the placental giant cells
and labyrinth (Figure 4B, bottom panels) compared to normotensive pregnancies.
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Figure 2. Sustained activation of placental CSR pathways in SHRSP pregnancies. (A) Schematic
diagram summarizing the CSR and antioxidant defense pathways investigated in this study. NADPH
oxidase (NOX) activation or increased activity of the mitochondrial electron flux leads to accumu-
lation of superoxide (O2•−), which under normal conditions is rapidly dismutated to hydrogen
peroxide (H2O2) by superoxide dismutases (SOD1, SOD2). H2O2 can readily diffuse through mem-
branes to react with proteins and DNA and is detoxified by cellular peroxidases (catalase (Cat)
and the peroxiredoxin/thioredoxin systems (PRX/TRX)). Failed detoxification of ROS produces
peroxynitrite (ONOO−) and hydroxyl radicals (OH•), promoting the nitration of membrane proteins
and the lipid peroxidation cascade. (B) Analysis of lipid peroxidation in both pregnancy models as
assessed by quantification of placental TBARS. (C) Analysis of protein nitrotyrosine (pNT) levels
in maternal (mesometrial triangle, top panel) and trophoblastic (placenta, bottom panel) layers of
WKY and SHRSP implantations as analyzed by immunohistochemistry. (D) Immunohistochemical
analyses of the expression of CSR chaperones hsp27 (upper panels) and hsp70 (bottom panels) in
both models. (E) Evaluation of placental NOX activation in both pregnancy models as indicated by
Western blot analyses of total and phosphorylated p47phox levels. The results are expressed as the
means ± SEM, n = 5–7 animals/group. In all the panels, * p < 0.05, ** p < 0.01 and *** p < 0.001 as
evaluated by two-way ANOVA and Bonferroni post-hoc tests.
As for complex N-glycans, PHA-L staining revealed a significant upregulation of ex-
pression levels in the mesometrial triangle and all placental compartments with progression
of normal pregnancy (Figure 4C). SHRSP placentas showed similar kinetics of expression
compared to WKY, except for significantly decreased levels of N-glycan expression in the
mesometrial triangle (Figure 4C, upper panels), placental giant cells and junctional zone
(bottom panels) at the onset of the SPE syndrome. On GD18, in contrast, SHRSP placentas
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displayed increased N-glycan levels in the giant cell layer compared to the normotensive
controls (Figure 4C, bottom panels).
Figure 3. SHRSP placentas display defective expression of antioxidant systems. (A) Western blot
analyses of the expression of ROS-detoxifying enzymes SOD1 (left panel), SOD2 (middle panel)
and catalase (right panel) in WKY vs. SHRSP placentas. Normal upregulation of SOD2 expression
towards GD18 was abrogated in SHRSP pregnancies. (B) Immunohistochemical analysis of PRX
expression in both models. (C) Placental expression levels of TRX in both models as assessed by
immunohistochemistry. The results are expressed as the means ± SEM, n = 5–7 animals/group. In all
the panels, * p < 0.05, ** p < 0.01 and *** p < 0.001 as determined by two-way ANOVA and Bonferroni
post-hoc tests.
Our analysis further revealed that progression of normal pregnancy was linked with a
significant upregulation of α2,3- (MAA, Figure 4D, upper panels) and α2,6-linked sialic
acid (SNA-I, Figure 4D, bottom panels) content in all compartments of the WKY placenta
from GD14 to GD18. Notably, despite similar kinetics of expression with pregnancy
progression, SHRSP placentas displayed increased levels of α2,3-sialylation in the decidua
and mesometrial triangle (Figure 4D, upper panels) and α2,6-sialylation in the mesometrial
triangle (bottom panels) on GD14 compared to WKY. On GD18, SHRSP placentas exhibited
increased α2,6-linked sialic acid content in the junctional zone compared to the controls
(Figure 4D, bottom panels).
3.3. Development of SPE Induces Changes in the Expression Profile of Stress-Sensitive Galectins in
the SHRSP Placenta
Our next aim was to define the galectin signature associated with progression of SPE
in the SHRSP model (Figure 5A), evaluating changes in the expression profile of stress-
sensitive galectins-1, -3 and -9 in the maternal and fetal compartments of the placenta
at the onset of disease (GD14) and upon full establishment of the syndrome on GD18.
Gal-1 was abundantly expressed in the GD14 placenta of both models, localizing to the
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cytoplasm and extracellular matrix of interstitial cells within the mesometrial triangle,
giant cells of the junctional zone and the placental labyrinth. In the maternal compartment,
normal pregnancy progression was associated with a significant upregulation of Gal-
1 expression from GD14 to GD18 (Figure 5B, left panel). SHRSP pregnancies showed
expression levels comparable to WKY on GD14 but the normal increase of Gal-1 associated
with pregnancy progression was abrogated in this model, exhibiting significantly decreased
levels compared to controls on GD18. In the SHRSP placenta, expression of Gal-1 remained
unchanged with pregnancy progression (Figure 5B, right panel), resulting in significantly
decreased levels of this galectin compared to controls on GD18.
Figure 4. Lectin-based profiling of the placental glycophenotype associated with SPE progression.
(A) Schematic representation of the O- and N-glycan moieties recognized by the lectin panels used in
the present study. (B) Placental expression levels of O- (HPA and PNA lectins, upper and middle
panels, respectively) and polyLacNAc-extended glycans (LEA, bottom panels) in both models.
Results are expressed as mean fluorescence intensity (MFI). (C) Analysis of the expression of complex
branched N-glycans in the different placental layers as assessed by PHA-L binding. (D) Levels
of terminal α2,3- (MAA, top panel) and α2,6-sialylation (SNA-I, bottom panel) in both pregnancy
models. The results are presented as the means ± SEM, n = 5–7 animals/group. In all the panels,
* p < 0.05, ** p < 0.01 and *** p < 0.001 as evaluated by two-way ANOVA and Bonferroni post-hoc tests.
Staining for Gal-3 was most prominent in the maternal compartment, but was also de-
tected in moderate levels within the junctional zone and strongly expressed in the labyrinth
layer of both mating models, showing mostly a cytoplasmic and extracellular matrix as-
sociation. Maternal expression of Gal-3 was similar in both models with a significant
downregulation as gestation progressed from GD14 to GD18 (Figure 5C, left panel). In the
placenta, in contrast, normal pregnancy progression was associated with a marked upreg-
ulation of Gal-3 expression (Figure 5C, right panel). Of note, SHRSP placentas exhibited
significantly increased expression of Gal-3 compared to WKY on GD14 but a significant
downregulation of this galectin associated with pregnancy progression (Figure 5C, right
panel), which resulted in decreased levels versus control placentas at GD18.
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Figure 5. Temporal variation of the placental galectin signature associated with the development
of SPE in SHRSP pregnancies. (A) Schematic diagram depicting the specific glycan moieties recog-
nized by the different stress-sensitive galectins determined in this study. (B) Immunohistochemical
analysis of Gal-1 expression in maternal (mesometrial triangle, left panel) and trophoblastic layers
(placenta, right panel) of WKY and SHRSP implantations. SHRSP placentas failed to upregulate
Gal-1 expression as gestation progressed to GD18. (C) Placental galectin-3 expression levels in both
pregnancy models. Onset of SPE was marked by a significant upregulation of Gal-3 in trophoblastic
compartments of the SHRSP placenta. (D) Immunohistochemical evaluation of Gal-9 expression in
both models. SHRSP displayed decreased trophoblastic expression of Gal-9 on GD14, with a failure
to upregulate levels of this lectin towards GD18. The results are presented as the means ± SEM,
n = 5–7 animals/group. In all the panels, * p < 0.05, ** p < 0.01 and *** p < 0.001 as evaluated by
two-way ANOVA and Bonferroni post-hoc tests.
Expression of Gal-9 on GD14 showed a similar pattern in both models, being detected
at moderate levels mainly with cytosolic localization to cells within the mesometrial triangle
and the placental labyrinth. No differences in mesometrial triangle Gal-9 were observed
as gestation progressed in any of the models, which showed similar expression levels of
this galectin at both days analyzed (Figure 5D, left panel). In contrast to WKY, labyrinth
expression levels of Gal-9 in the SHRSP model were not modified as gestation progressed
to GD18 and were significantly lower than in WKY pregnancies at both days analyzed
(Figure 5D, right panel).
4. Discussion
Impaired placental function is generally assumed as the major contributor to develop-
ment of SPE, yet pathophysiological evidence in support of this notion is relatively scarce.
In this study, we demonstrated that onset of SPE in SHRSP pregnancies is characterized by
a persistent activation of the placental CSR linked with a prominent decrease of placental
core 1 O-glycans. These changes were associated with increased sialylation in the maternal
compartments, providing novel insights on dysregulated molecular pathways associated
with placental insufficiency in pregnancies affected by chronic hypertension. We further
observed marked changes of the placental galectin signature, highlighting the paramount
role of these proteins as dynamic “sensors” of microenvironmental challenges affecting the
placental glycoredox status.
Our analysis of the placental CSR first revealed significant temporal changes in mark-
ers of lipid peroxidation, nitrosative stress, heat shock protein expression and NOX2
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activation in WKY placentas, indicating that activation of the CSR is a feature of normal
pregnancy progression. Pregnancy per se imposes a physiological cellular stress, as normal
placental development involves extensive cell division, high metabolic rates and temporal
fluctuations in oxygen tension [31]. In the rat placenta, establishment of the hemochorial
interface around GD12 followed later by a progressive rise in blood flow imposed by
the rapid growth of the labyrinth towards term are important gestation stage-dependent
environmental challenges determining oxygen exposure [32–34]. In this context, an im-
portant adaptive response to limit tissue damage involves a parallel temporal increase in
placental antioxidant defenses as verified in normally progressing pregnancies [31,35,36].
Thus, the temporal changes in the expression of antioxidant enzymes SOD1, SOD2 and
catalase, which are part of the first line of defense against oxidative damage, suggest that
the placental ROS-detoxifying capacity in WKY pregnancies is sufficient to overcome tissue
damage reflecting an effective adaptive response [36].
Two main deviations of the normal placental CSR profile were observed in SHRSP
associated with progression of the SPE syndrome. First, both placental compartments ex-
hibited a significant upregulation of CSR markers on GD14, indicating that onset of disease
involves an exaggerate activation of the placental stress response and defective antioxidant
expression. The presence of sustained oxidative stress due to persistent malperfusion
would in turn accelerate the CSR resulting in premature ageing of the placenta. In particu-
lar, the failure to upregulate SOD2 expression towards GD18 observed in SHRSP placentas
may be indicative of an underlying mitochondrial dysfunction, which is becoming increas-
ingly recognized as a mechanism involved in preeclampsia pathogenesis [37–40]. Indeed,
mitochondrial function appears to be differentially regulated in preeclampsia subtypes
(i.e., early-onset vs. late-onset [38]) and mitochondrial adaptations including upregulated
SOD2 activity play a paramount role in determining successful outcomes in preeclamptic
pregnancies [39]. Of note, mitochondrial dysfunction can arise as a direct consequence of
placental ischemia–reperfusion injury, as has been observed in the reduced uterine per-
fusion pressure (RUPP) model of preeclampsia [37] and also in healthy human placentas
exposed to in vitro hypoxia/reoxygenation [39] It is therefore plausible that mitochondrial
stress results from failed arterial remodeling in the SHRSP [11], which would allow highly
pressured intermittent pulses to reach the placental site and cause ischemia–reperfusion
damage to trophoblasts. Alternatively, a contribution of maternal pre-existing disease to
mitochondrial dysfunction cannot be ruled out. Indeed, SHRSP display dysregulated basal
expression of genes involved in mitochondrial ROS homeostasis (i.e., UCP2 [41], which
in normal pregnancies has been shown to take part in the protective placental response
associated with rapid growth of the labyrinth layer towards term [36]). Second, later on
GD18, the sustained activation of stress pathways during earlier stages would compromise
cell organizational processes involved in normal placentation, rendering the placenta with
a limited ability to effectively adapt to later challenges. An earlier oxidative injury during
the critical period of placental morphogenesis could account for the remarkable structural
alterations observed in the SHRSP associated with placental insufficiency. For instance,
AldhIA3-expressing glycogen trophoblasts, which are significantly depleted from the
junctional zone in SHRSP placentas [11,42], appear to be selectively vulnerable to ischemia–
reperfusion damage associated with enhanced endothelin 1 signaling [43]. Although the
precise significance of these pathways in connection with SPE requires further investigation,
our results suggest that placental insufficiency and consequent FGR in SHRSP could result
from failed organizational processes during early placental morphogenesis in the context
of sustained exaggerated activation of CSR pathways.
Hypertensive disorders of pregnancy impose a deviation of the placental glycopat-
terns and aberrant glycosylation of plasma proteins [44,45]. However, the relationship
between the onset of disease and the placental glycophenotype has not been described.
To the best of our knowledge, our study constitutes the first characterization of changes
in galectin–glycan circuits associated with progression of SPE in chronic hypertensive
pregnancies. Our lectin-based profiling of glycan expression revealed significant alterations
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in placental O-glycosylation coupled with maternal compartment-specific changes in sialy-
lation associated with onset of disease in SHRSP pregnancies. Overall, SHRSP placentas
displayed a significantly decreased expression of the TF antigen (core 1, Galβ1-3GalNAc)
associated with onset of disease and downregulation of the Tn antigen (GalNAc) levels
in the labyrinth layer as gestation progressed to GD18. Since core 1 O-glycans showed
a reduction in SHRSP placentas, we hypothesize that progression of SPE is linked with
an overall reduction of O-glycan synthesis. Another possible explanation is enhanced
sialylation of the Tn antigen, which would interfere with HPA binding and thus prevent
detection of the antigen. Since other glycan structures like core 1 and polyLacNAc se-
quences are reduced in SHRSP placentas but α2,6-sialylation seems to be increased, activity
of the corresponding glycosyltransferase ST6GalNAc1 [46,47] might be responsible for
increased sialylation of the Tn antigen because other structures are less available. Important
pregnancy-relevant carriers of the sialyl-Tn antigen are mucin 1 (MUC1), CD44, integrins
and osteopontin, all of which play roles in placental well-being [48–51]. In particular, loss of
heavily O-glycosylated MUC1 in human placenta is associated with inflammation in preg-
nancies affected by preeclampsia and choriamnionitis [52,53]. MUC1 is also expressed in
mouse trophoblast cells and its expression is regulated by peroxisome proliferator-activated
receptor γ (PPAR-γ) [54], which is linked to preeclampsia in humans and rats [55–57].
While less prominent than for O-glycosylation, our study also revealed changes in
N-glycans associated with SPE progression. Complex N-glycans belong to the major lig-
ands for Gal-1 and 3 at cell surfaces [58]. The addition of GlcNAc in a β1,6 linkage to the
N-glycan core by the enzyme Mgat5 initiates branching leading to tri- and tetra-antennary
N-glycans, which display increased affinity for galectin binding [59]. Furthermore, Mgat5
products are the preferred substrate for addition of polyLacNAc sequences, which also
enhances affinity for Gal-1 and -3 [60]. In this study, the plant lectins PHA-L and LEA were
used to detect the Mgat5 product and polyLacNAc sequences, respectively. Of note, poly-
LacNAc sequences are also present on extended core 2 O-glycan structures. We revealed a
reduction of Mgat5 products mainly in placental compartments of SHRSP implantation
sites on GD14 (i.e., spongiotrophoblasts and giant cells), followed by decreased levels
of polyLacNAc extensions later on GD18. These findings indicate that galectin binding
may be impaired due to reduced amounts of their target sequences. Interestingly, galectin
binding to polyLacNAc extensions of MUC1 O-glycans has been shown to prevent NK cell
attack on tumor cells [61]. This finding suggests that reduced abundance of polyLacNAc
sequences may indicate loss of MUC1 function and, hence, persistent inflammation in
SHRSP placentas due to reduced protection against maternal immune cell activation.
Sialylation corresponds to the addition of sialic acids, which are typically found
attached to the distal end of glycans. Sialic acids can be attached to O- as well as N-glycans
via an α2,3 or α2,6 bond. Of note, the addition of α2,6-linked sialic acid prevents LacNAc
recognition by Gal-1 and -9, possibly because these lectins primarily recognize terminal
LacNAc units [60]. In contrast, Gal-3 is less influenced by this type of sialylation due to
its ability to recognize internal LacNAc motifs [62]. In the current study, we observed
an increase of both types of terminal sialylation in the maternal compartments of SHRSP
implantations on GD14, followed by a decrease of α2,3-linked residues in the decidua and
the labyrinth on GD18. The predominant increase of α2,3-sialylation on GD14 may be a
compensatory mechanism to enhance galectin binding since, as discussed previously, other
major glycan structures for galectin binding seemed to exhibit an overall reduction. Of
note, important carriers of sialylated glycans in the placenta are PECAM-1 and VEGFR2
and it has been proposed that since endothelial cells express the enzyme for α2,6- as
well as α2,3-sialyation, different sialyltransferases might be responsible for modulation
of specific sialylation influencing homo- and heterophilic interactions and the binding of
different angiogenic growth factors to these receptors [63,64]. In addition, it has been shown
that sialylation is crucial for protection of fetal cells from maternal immune attack [65],
suggesting that the reduction of α2,3-sialyation on GD18 in the decidua and labyrinth may
account for increased maternal immune activation in these compartments.
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A feature of preeclamptic placentas is dysregulation of the autophagy process, which
prevents the maintenance of cellular homeostasis [66]. Interestingly, it has been shown
that autophagy is important for human trophoblast functions, including invasion and
vascular remodeling in extravillous trophoblasts, which are crucial for normal placental
development [67]. Similar results have been observed in vivo by using a placenta-specific
Atg7 (essential for autophagy) conditional knockout mouse model [68], which results in
autophagy deficiency accompanied by poor placentation and elevated maternal blood
pressure, suggesting its correlation with the pathophysiology of PE. Notably, both Gal-3
and Gal-9 have been implicated in the control of autophagy, acting as negative (Gal-3 [69])
and positive (Gal-9, mediated by polyLacNAc recognition [70,71]) modulators, respectively.
These findings are in agreement with our observation that SHRSP implantations exhibited
decreased Gal-9 and upregulated Gal-3 levels already at the onset of the disease and re-
duced polyLacNAc presentation (LEA staining) in placental compartments, which would
possibly lead to impaired autophagy und thus cellular stress. Moreover, Sudhakar et al.
showed that compromised autophagy due to loss of Gal-9 in mouse pancreatic and intesti-
nal cells contributes to increased susceptibility to disease pathogenesis [71]. These findings
led to the assumption that highly secretory cells (i.e., placental cells) are protected from
endoplasmic reticulum stress and apoptosis via Gal-9-mediated autophagy that would
otherwise lead to tissue inflammation or injury.
5. Conclusions
Overall, there seems to be a severe dysregulation of glycosylation in all compartments
of SHRSP implantation sites, possibly caused by the early and sustained activation of
CSR pathways (Figure 6). The observed changes in glycosylation which already occur
on GD14 with the onset of disease before establishment of the maternal syndrome may
account for altered cellular responses to environmental stimuli as well as cellular growth
and differentiation patterns since glycans have multiple crucial roles in these processes.
This assumption is further strengthened by the fact that galectins are important translators
of the glycocode and the changes observed in this study for SHRSP implantations most
likely led to reduced galectin binding on the cell surfaces. Thus, our findings uncovered a
new role for the glycoredox status in promoting the development of SPE representing a
promising mechanism in the pathogenesis of hypertensive disorders during gestation.
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Figure 6. Summary of the placental molecular pathways involved in the pathogenesis of SPE in
SHRSP pregnancies. Abbreviations: MT, mesometrial triangle; GC, giant cells; JZ, junctional zone;
SpA, spiral artery. We hypothesize that as a result of placental malperfusion, early and sustained
activation of CSR pathways intimately linked to impaired glycosylation (i.e., dysregulation of the
so-called glycoredox system) would cause a premature aging of the placenta. This response would in
turn provoke exhaustion of the placental defense systems, rendering the placenta unable to effectively
adapt to later challenges. This local stress response is finally translated systemically leading to full
establishment of the SPE syndrome towards term.
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